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Abstract
Objective—Phase 0 studies can provide initial pharmacokinetics (PK) data in humans and help
to facilitate early drug development, but their predictive value for standard dosing is controversial.
To evaluate the prediction of microdosing for active intracellular drug metabolites, we compared
the PK profile of two antiretroviral drugs, zidovudine (ZDV) and tenofovir (TFV), in microdose
and standard dosing regimens.
Study Design—We administered a microdose (100 μg) of 14C-labeled drug (ZDV or tenofovir
disoproxil fumarate (TDF)) with or without a standard unlabelled dose (300 mg) to healthy
volunteers. Both the parent drug in plasma and the active metabolite, ZDV-triphosphate (ZDV-
TP) or TFV-diphosphate (TFV-DP) in PBMCs and CD4+ cells were measured by AMS.
Results—The intracellular ZDV-TP concentration increased less than proportionally over the
dose range studied (100 μg to 300 mg), while the intracellular TFV-DP PK were linear over the
same dose range. ZDV-TP concentrations were lower in CD4+ cells versus total peripheral blood
mononuclear cells (PBMCs), while TFV-DP concentrations were not different in CD4+ cells and
PBMCs.
Conclusion—Our data were consistent with a rate-limiting step in the intracellular
phosphorylation of ZDV but not TFV. AMS shows promise for predicting the PK of active
intracellular metabolites of nucleosides, but nonlinearity of PK may be seen with some drugs.
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INTRODUCTION
The development of analytical techniques such as accelerator mass spectrometry (AMS) and
highly sensitive LC-MS/MS allows assessment of bioavailability and plasma
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pharmacokinetics (PK) in human subjects using a microdose (less than 100 μg) of drug 1–3.
Microdosing studies would allow early screening in human before extensive animal toxicity
studies and GMP scale-up for phase I clinical studies to help identify the most promising
drug candidates. It is not clear whether the kinetics of a microdose of a drug in vivo can
predict the PK of a much larger therapeutic dose. However, there is mounting evidence that
microdosing results are predictive of plasma PK and metabolism at the therapeutic dose
level across a wide range of different chemical classes 4, 5.
The efficacy and toxicity of many human drugs depend on transport into target cells
followed by conversion to an active or toxic metabolite. There are many nucleoside analog
drugs whose efficacy depends on intracellular phosphorylation, including those used in anti-
HIV treatment, viral hepatitis and cancer. Little is known about the PK of intracellular
phosphorylation of these drugs in microdosing studies. In a previous trial, we have
demonstrated that it is feasible to detect 14C-labeled zidovudine triphosphate using AMS
technology with high sensitivity, and we have successfully cross-validated these results
using standard LC/MS/MS analysis 6. With this technique we can thus directly compare the
PK of intracellular phosphorylation in microdose and standard dose studies. Zidovudine
(ZDV), a thymidine analog, and tenofovir (TFV), an adenosine analog, are nucleoside/
nucleotide reverse transcriptase inhibitors (NRTI’s) used in HIV treatment and prevention.
These drugs are phosphorylated by different intracellular pathways 7, 8. We used 14C-labeled
ZDV and 14C-labeled tenofovir disoproxil fumarate (TDF) as model drugs to compare the
PK of the active intracellular phosphorylated anabolite (ZDV-triphosphate, or ZDV-TP, and
TFV-diphosphate, or TFV-DP), in total peripheral blood mononuclear cells (PBMC’s) and
isolated CD4+ T cells in vivo with both a microdose regimen and a standard dose regimen
using AMS.
The PK of the active intracellular drug metabolite is important in evaluating the efficacy and
toxicity of a drug and in choosing a dosing regimen. Evidence suggests that ZDV
phosphorylation may be greatly reduced in CD4+ lymphocytes9, which are the major target
population for HIV infection, but no direct comparisons of TFV phosphorylation in T-cell
subsets have been published. Here we directly compare TFV-DP and ZDV-TP measured in
PBMCs and CD4+ T cells in subjects receiving a microdose or therapeutic dose of TDF.
METHODS
Subjects and study design
This protocol was reviewed and approved by the Johns Hopkins Medicine Institutional
Review Board (IRB) and Radioactive Drug Review Committee (RDRC), and all subjects
signed informed consent approved by the IRB. All subjects underwent a screening history
and physical examination up to 28 days prior to participation. Enrolment criteria included
age 18–55 years, normal renal function based on calculated creatinine clearance,
hemoglobin >12 g/dL, HIV seronegative, and no medications or dietary supplements within
7 days prior to the study. No medications or supplements were allowed during the study.
This was a fixed-sequence study with two arms (ZDV arm and TDF arm). Six healthy
subjects were enrolled for each arm. All twelve subjects received a microdose (20 μCi/100
μg) of 14C labeled drug (ZDV or TDF) at first visit, and after a washout period of at least 30
days, all subjects received a standard dose (20 μCi/300.1 mg) of drug (ZDV or TDF).
Detailed dosing information is described in supplemental Digital Content 1.
Chemicals and Materials
14C-labeled ZDV [2-14C-], ZDV-TP, and 14C-labeled TDF [adenine-8-14C-] were obtained
from Moravek Biochemicals, Inc. (Brea, CA). HPLC-grade water and methanol were
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purchased from VWR (Bridgeport, NJ). Analytical grade potassium chloride, sodium
acetate, and acid phosphatase were acquired from Sigma-Aldrich Corp. (St Louis, MO).
Waters XTerraR MS C18 2.5 μm, 2.1×50mm columns, Waters Accell™ Plus QMA
Cartridges, and Waters OASISR® HLB Extraction Cartridge were purchased from Waters
Corporation (Milford, MA).
Sample collection and processing
PK samples for plasma, PBMC’s and fractionated CD4+ T-lymphocytes were obtained
predose, 2, 4, 8, 12, and 24 hours postdosing in the ZDV arm, and predose, 4, 12, 24, 72,
and 168 hours postdosing in the TDF arm. At designated time points, 40 mL of blood was
collected from each subject in CPT tubes (Becton, Dickinson and Company, Franklin Lakes,
NJ) for the isolation of PBMCs. Two-thirds of the PBMCs were used to isolate CD4+ cells
by MACS cell separation with CD4 microbeads and LS columns (Miltenyi Biotec, Bergisch
Gladbach, Germany), as previously described 10. Cells were washed and counted. 4 mL
plasma was saved from the same samples for later PK analysis of parent drug
concentrations.
For PBMC’s and CD4+ cells obtained from 40 mL of blood, cells were counted and lysed as
107 cells/250 μl buffer (70% methanol) and stored at −80 °C.. Samples with cell counts less
than 107 werelysed in 250 μl buffer. All cell extracts were processed using solid phase
exchange cartridges to separate ZDV/TFV phosphates from parent drug and other
anabolites, as described 11, 12. Phosphate fractions and plasma samples were sent on dry ice
for analysis by AMS.
AMS and PK analysis
AMS analyses (see Supplemental Digital Content 1) were conducted at the MIT BEAMS
Lab using procedures described elsewhere in detail 13. PK parameters were derived by
noncompartmental analysis using WinNonlin (Pharsight, Sunnyvale, CA) version 5.0.1. The
elimination rate constant (ke) was determined from the natural log-transformed data, using
linear regression analysis. Elimination half-life was calculated from the following equation:
t1/2=In2/Ke. All values below the limit of quantification (BQL) before Tmax was set at 0; the
first BQL value after Tmax was set at half the BQL value; the rest of BQL readings were not
used in the analysis.
Statistical analysis
To compare the PK profiles between the microdose and standard dose regimen, we
performed the Wilcoxon signed rank test. The same test was used to determine PK
differences in CD4+ cells and PBMCs. A p value <0.05 was considered to be statistically
significant. All statistical analyses were performed by SPSS 19.0(IBM, Armonk, NY).
RESULTS
Clinical study
Twelve HIV-seronegative subjects (11 male, 1 female; 8 African Americans and 4
Caucasians), ages 35–55 years old, BMI 20.1–31.5 kg/m2, were randomized into two arms.
All subjects tolerated study procedures without clinically significant adverse events.
Detection of parent drug and intracellular triphosphates
The AMS data were reported as dpm/mL and converted to mass concentrations as
previously described 6, based on a drug ratio of 100 μg drug/20 μCi for the microdose
phase, and 300.1 mg drug/20 μCi for the standard dose phase. Only AMS analysis was
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carried out on these samples because of assay sensitivity limits for LC-MS/MS in the
microdose phase, and based on prior comparisons of the accuracy of AMS versus LC-MS/
MS, with correlation coefficient of 0.96 and ratio of AMS to LC-MS/MS measurement at
1.03 (90% confidence interval 0.92–1.17) 6.
For ZDV, in all postdose samples for all six subjects, ZDV and ZDV-TP were detectable by
AMS. For TFV, TFV-DP was not detectable in the CD4+ cell subset postdose in the
microdose regimen for a single subject. For both drugs, predose samples in plasma for the
second phase of the study were all below detection limits by AMS. In PBMC’s, two subjects
in each arm had a higher than LLOQ signal at predose during the second phase of the study,
although these concentrations were barely higher than the LLOQ. The normalized carryover
from microdose phase were less than 1% of standard dose Cmax for ZDV-TP, and less than
5% of standard dose Cmax for TFV-DP in predose samples. LLOQ values were never higher
than 0.021 dpm/mL but they varied as a function of instrument condition.
Comparison of plasma PK following a microdose versus a standard therapeutic dose of
NRTI’s
In the ZDV arm, the concentration-time plot (Figure 1a) shows that the total plasma 14C
(including both 14C-ZDV and its major metabolite 14C-ZDV-glucuronide as AMS cannot
discriminate between these moieties) was similar comparing the microdose and standard
dosing regimens. With our limited sampling time points, Tmax occurred at 2 hours for all
subjects in both dosing regimens. For the microdose regimens, normalized median Cmax for
ZDV equivalent (parent drug plus circulating metabolites) was 0.7-fold lower compared to
that of the standard dose (Tables 1 and 2). In all six subjects, calculated Cmax was lower
with the microdose regimen (Wilcoxon signed rank test, p=0.03), while the microdose
predicted AUCinf was higher in one subject and lower in five subjects (Wilcoxon signed
rank test, p=0.08). Noncompartmental analysis calculated plasma ZDV clearance (CL/F),
apparent volume of distribution (Vd/F) and half-life for both microdose and standard dose
(Table 1). The ratios of all PK parameters derived from the two dosing regimens were
within a factor of two (Table 2), indicating reasonable concordance of ZDV plasma PK as
assessed by the microdose and standard dose.
For the TDF arm, 14C signal in plasma is mostly TFV 14, 15. The concentration-time plot is
shown in Figure 1b. With the microdose regimen, normalized plasma TFV concentrations
were higher compared to the standard dosing regimen (Figure 1b). The Tmax for plasma
TFV was detected at 4 h for all subjects in both regimens. For the microdose regimen,
median normalized Cmax and AUCinf were 1.5 times higher compared to that of the standard
dose. Normalized Cmax and AUCinf calculated after the microdose were higher in all six
subjects (Wilcoxon signed rank test, p=0.03). Noncompartmental analysis showed that all
the plasma PK parameters (clearance (CL/F), apparent volume of distribution (Vd/F) and
half life (T1/2)) were similar in microdose and standard dose regimens, with ratios less than
two (Tables 1 and 2).
Comparison of PK of intracellular phosphorylated metabolites following a microdose
versus a standard therapeutic dose of NRTI’s
Figure 1c and d illustrate the concentration-time plots for ZDV-TP in total PBMC’s and
isolated CD4+ cells. The Tmax for intracellular ZDV-TP was observed at 2 hours for all cell
types, and the intracellular 14C-ZDV-TP Cmax and AUCinf were higher with the microdose
regimen for all six subjects (p=0.03) for both PBMC and CD4+ cells. In PBMCs, the median
ratio of normalized Cmax for ZDV-TP was 4.5-fold higher (291.9 versus 85.5 fmol/106 cells)
after the 100 μg microdose versus 300 mg dose of ZDV. In the CD4+ cells, the median
normalized Cmax of intracellular ZDV-TP was 17-fold higher (204.2 versus 15.0 fmol/106
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cells)after microdosing compared to standarddosing (Table 1 and 2). Noncompartmental
analysis indicated that for PBMC’s, the AUCinf of intracellular ZDV-TP changed 3.9-fold
over the dose range studied (100 μg to 300 mg). In CD4+ cells, the AUCinf of ZDV-TP
changed 12.9-fold over the same dose range (Table 2).
For TFV-DP, we observed a plateau between 12 to 72 hours post dose (Figure 2e and f). The
Tmax may be observed at any time point on the plateau, with the median at 24h for PBMC’s
and 72h for CD4+ cells. The median normalized Cmax in total PBMC’s for TFV-DP was
comparable after microdosingversus after the standard dose (13.1 versus 10.4 fmol/106 cells,
p=0.35). In CD4+ cells, the median normalized Cmax of intracellular TFV-DP was 1.6-fold
higher versus after receiving the standard dose (13.17 versus 5.11 fmol/106 cells, p=0.08,
Table 1 and 2). In Wilcoxon signed rank test, the normalized intracellular TFV-DP AUCinf
was 1.43-fold and 1.28-fold greater with the microdose when compared to the standard dose
for PBMC’s and CD4+ cells, respectively (p>0.05 for both, Table 2). Half-life estimation
based on only two terminal time points was similar between the two dosing regimens.
Comparison of PK of intracellular phosphates in CD4+ cells and PBMC’s
Intracellular ZDV-TP concentrations were lower in CD4+ cells (p=0.03) compared to
PBMC’s in subjects receiving the standard dose regimen, but this difference was smaller and
not statistically significant following the microdose regimen (p=0.08, Table 3). The median
ratio of the PBMC to CD4+ cell AUCinf was 3.81 (range 2.10–6.37) for the standard dose
regimen and 2.00 (range 0.76–3.62) for the microdose regimen (Table 3). Half-life
estimation of ZDV-TP was not different for CD4+ cells compared to PBMCs in both dosing
regimens (Tables 1 and 3).
In both the microdose regimen and the standard dose regimen, TFV-DP showed a similar
PK profile for PBMC’s and CD4+ cells (p>0.05 for Cmax, AUCinf, and t1/2). The median
ratio of PBMC’s to CD4+ cell AUCinf was 1.04 (range 0.48–2.72) for the microdose
regimen and 2.15 (range 0.79–3.55) for the standard dose regimen (Table 3).
In comparing PK parameters calculated after the microdose or standard dosing regimens in
this specific target cell subset, CD4+ cells demonstrate the same trend as PBMC’s. For
ZDV-TP, estimated Cmax and AUCinf were higher after the microdose compared to the
standard dose in both CD4+ cells and total PBMC’s. For TFV-DP, no statistically
significant difference in TFV-DP PK was observed between the microdose and standard
dosing regimens in either CD4+ cells or PBMC’s (Tables 1 and 2).
The biphasic elimination of intracellular TFV-DP
Following the standard dosing regimen, intracellular TFV-DP concentrations peaked around
12 hours postdosing, then plateaued between 12–72 hours (Figure 2a). After the plateau,
there was a slow elimination phase with an estimated T1/2 of 64h and 100h in PBMC and
CD4+ cells, respectively, but based on only two terminal timepoints (72 and 168 hours
postdosing). This biphasic profile was observed in 5 out of 6 subjects. Figure 2a plots the
plasma TFV and intracellular TFV-DP of PBMC after a single dose of 300 mg TDF. The
TFV-DP concentration continued to increase even after the TFV concentration in plasma
dropped to near background.
Figure 2b illustrates the ratio of absolute molar concentration of extracellular TFV and
intracellular TFV-DP (with a volume of 0.4 μl per million cells used to estimate
concentration 16, 17). The molar ratio of plasma to intracellular TFV-DP was around 100-
fold at 4 hours post dose, and declined to around 2-fold at 72 hours, then fell below 1.0 at
168 hours. These results indicated that the positive concentration gradient of TFV between
plasma and intracellular compartments persisted until 72 hours post dosing.
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DISCUSSION
In this study, we examined the PK profile of two NRTI’s after microdose and standard
therapeutic dosing regimens. For zidovudine, plasma PK showed linearity over a 3000-fold
dosing range, but the normalized intracellular ZDV-TP was several folds higher with the
microdose compared to the standard dosing regimen. For TFV, the normalized plasma
AUCinf was 1.5-times higher with the microdose regimen, possibly indicating higher oral
bioavailability, but intracellular TFV-DP PK was linear over the 3000-fold dose range
tested. As has been suggested previously, the ability to precisely predict human PK from a
microdosing study will vary from molecule to molecule 18–20.
The different results for intracellular ZDV-TP and TFV-DP may reflect the different kinases
involved in their phosphorylation pathways. ZDV is phosphorylated sequentially by
thymidine kinase, thymidylate kinase, and NDP kinase, with thymidylate kinase acting as a
rate-limiting enzyme in this process21. An earlier study showed that the phosphorylation of
ZDV-MP to ZDV-DP is characterized by a high Km and low Kcat, and that intracellular
ZDV-MP concentrations were much lower than the Km of this enzyme after a 300 mg dose7.
Since the concentration of ZDV-MP is likely to be far below the Km with either the standard
300 mg dose or the microdose (100 μg), the rate of conversion of ZDV to ZDV-TP should
be similar in either case. However, ZDV-MP has been reported to have a substrate
suppression effect on thymidylate kinase 21. With microdose of ZDV, this suppression might
be reversed and the enzyme may become more efficient. This could have contributed to the
higher ZDV phosphorylation observed with the microdose regimen.
Tenofovir is phosphorylated by adenylate kinase to TFV-MP, and subsequently
phosphorylated by nucleoside diphosphate kinase (NDPK) to TFV-DP. In vitro data suggest
that this second step can also be accomplished by pyruvate kinase and creatine kinase 22.
With TFV and TFV-MP as substrates, both phosphorylation steps are also characterized by
low Kcat and high Km22, 23. In other words, phosphorylation is carried out at low velocity
and high capacity, which may explain the slow accumulation of TFV-DP in cells and the
linearity of PK across the 3000-fold range of doses we evaluated in this study.
Studying phosphorylation in the biological target cell subset in vivo may provide valuable
information applicable to future drug use and development. It has been reported that ZDV-
TP formation is lower in CD4+ cells than in total PBMCs, while lamivudine triphosphate
concentrations are the same amongst different cell types9. Here we compared the
intracellular phosphorylated concentrations of ZDV and TFV in CD4+ cells versus total
unfractionated PBMCs. ZDV-TP concentrations were lower in CD4+ cells in the standard
dose regimen, while TFV-DP concentrations were not different in these subsets of cells.
The reason for the different phosphorylation of ZDV in specific cell types is not fully
understood, and the result of this study supports the existence of a rate-limiting step, or
nonlinear phosphorylation specific to ZDV in CD4+ cells. The difference of ZDV-TP
concentrations in CD4+ cells compared to PBMCs was statistically significant with standard
dosing (Wilcoxon signed rank test, p<0.05), but not with microdosing. The difference in
ZDV-TP concentrations after microdose and standard dose regimens was larger in CD4+
cells compared to PBMC’s (11.9-fold versus 3.9-fold), unlike TFV-DP (similar
concentration ratios in PBMC’s and CD4+ cells after the two dosing regimens). These
observations further support the existence of a rate-limiting step in the formation of ZDV-TP
in CD4+ cells.
AMS analysisof the intracellular concentrations of ZDV-TP and plasma TFV yielded
excellent concordance with published data 11, 24–26. The longer estimated half-life and
higher AUCinf of ZDV in plasma in this study was almost certainly because AMS measures
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the sum of ZDV and its metabolites, mainly ZDV-glucuronide. For TFV-DP, single dose PK
for TFV-DP in PBMC has not been reported in the literature, and all PBMC TFV-DP data
were collected from subjects who have reached steady state. It is possible to estimate the
steady state Css based on the PK profile after a single dose if the PK is linear and stationary.
If we use Css=AUCinf/tau, the derived mean Css with 300 mg once daily dose is about 60
fmol/106 cells. This derived steady state TFV-DP concentration agrees with that reported in
the literature 2427–29.
We observed a significant plateau phase for intracellular TFV-DP concentrations between
12–72 hours following a single dose, followed by a more conventional but prolonged
elimination phase. A prolonged plateau phase suggests balanced formation and elimination
of TFV-DP. Estimation of the T1/2 of TFV-DP is complicated by this multiphasic
elimination, i.e., plateau phase followed by prolonged elimination phase, and this may
explain the wide range of elimination half-lives reported in vitro (50 h in resting T cells) 830
and in patients taking TDF (100–150 h) 2831. In our study, intracellular TFV-DP formation
appeared to continue as plasma TFV concentrations fell to undetectable levels. A detailed
calculation of the absolute ratio of concentrations of intracellular and extracellular TFV
found that the positive gradient from outside the cell to inside the cell persisted during the
TFV-DP formation and plateau phases and for up to 72 hours post dose (Figure 2b). This
suggests that it is not necessary to posit a reservoir or accumulation of intracellular TFV-DP
precursors such as TFV or TFV-MP. Recent data also proved little accumulation of TFV or
TFV-MP in PBMC’s in vivo27. Our single dose studies allowed demonstration of a
hysteresis of TFV-DP formation relative to plasma TFV, and a biphasic elimination profile
of TFV-DP elimination. This aspect of TFV-DP PK has not been reported previously in the
literature. These findings support the observations of Patterson’s study, where TDF-DP
concentrations were detectable in rectal and vaginal mucosal homogenates as long as 14
days following a single dose25.
TDF is widely used for the treatment of HIV infection, and also shows promise in
preexposure prophylaxis for HIV infection 32, 33. Our findings may have potential
implications for future prevention studies using TDF. The 12 hour time lag before the
beginning of the TFV-DP plateau following a single dose suggests that the first dose of TDF
for PrEP may need to be taken at least several hours prior to exposure in order to be
effective depending on the effective TFV-DP concentration. On the other hand, the long
plateau and slow elimination of TFV-DP indicates that a daily dosing regimen should be
quite forgiving of missed doses if used continuously.
For the comparison of microdose and standard dosing regimens, we used a fixed sequence
design with paired analysis to compensate for interindividual variability, our study was
therefore informative despite the small number of subjects. Carryover of intracellular
phosphates from the microdose phase was observed, but in only two subjects in each arm
and the amount was too small to significantly influence the results of the standard dose
phase. A fixed sequence design has the advantage over a crossover design of avoiding
potential consequences of induction or inhibition of drug metabolizing enzymes,
transporters, kidney function and other potential drug toxicities that might change PK after a
standard dose of ZDV or TDF. AMS may facilitate early development of investigational
nucleoside analogs through microdosing, but rate-limited metabolism complicates
interpretation of intracellular metabolism with microdosing studies. When rate-limiting steps
potentially present, caution should be exercised in extrapolating from microdose to standard
dose.
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Fig. 1.
Comparison of plasma and intracellular PK after the microdose (100 μg), and standard dose
(300 mg) Shown are concentration of ZDV equivalents or TFV in plasma (a,b), and
concentration of intracellular ZDV-TP or TFV-DP (c,d,e,f) in the 6 subjects (mean±sd),
normalized to a 300 mg dose, versus time. (A) Plasma concentration-time curve for ZDV
equivalents (includes ZDV, ZDV-glucuronide and other metabolite of ZDV in plasma) with
microdose regimen (circles, solid line) and standard dose regimen (squares, dashed line). (B)
Plasma concentration-time curves for TFV with microdose regimen (circles, solid line) and
standard dose regimen (squares, dashed line). (C) ZDV-TP concentration-time curve for
PBMCs with microdose regimen (circles, solid line) and standard dose regimen (squares,
dashed line). (D) ZDV-TP concentration-time curve for CD4+ cells with microdose regimen
(circles, solid line) and standard dose regimen (squares, dashed line). (E) TFV-DP
concentration-time curve for PBMCs with microdose regimen (circles, solid line) and
standard dose regimen (squares, dashed line). (F) TFV-DP concentration-time curve for
CD4+ cells with microdose regimen (circles, solid line) and standard dose regimen (squares,
dashed line).
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Fig. 2.
Biphasic elimination of TFV-DP after a single dose of TDF. (A) Overall results of PK after
a single dose (300mg) of TDF. The solid line represents the plasma TFV concentrations
(mean±sd). The dashed line represents the intracellular TFV-DP concentrations (mean±sd).
(B) Molar ratio (median ± range) of plasma TFV to intracellular TFV-DP in PBMC over
168h after dose with microdose regimen (circles, solid line) and standard dose regimen
(squares, dashed line).
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Table 3
PK parameter ratios of PBMC to CD4+ cells. Paired analysis, median (range)
Drug treatment t1/2 Cmax AUC0-inf
ZDV
microdose 1.11 (0.80–1.79) 1.80 (0.89–8.38) 2.00 (0.76–3.62)
standard dose 0.76 (0.48–0.86) 5.07* (1.99–12.71) 3.81* (2.10–6.37)
TDF
microdose 3.14 (0.97–6.28) 1.04 (0.48–2.72) 1.36 (0.76–2.75)
standard dose 0.84 (0.11–2.98) 2.15 (0.79–3.55) 1.31 (0.85–1.57)
*p<0.05, Wilcoxon signed rank test.
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